Can AI help biopharma identify the next blockbuster?

A Feature on M&A, licensing, and partnership tapping into AI’s potential to improve drug development.

Artificial intelligence (AI) is at the intersection of healthcare and drug development and promises to support scientists in their quest to identify new targets and design novel molecules to address areas of high unmet medical needs. Over the last decade, investment in AI-driven pharma and biotech has skyrocketed, reaching over $60 billion. According to the McKinsey Global Institute (MGI), generative AI technologies could generate $60 billion to $110 billion a year in economic value for the pharma and medical-product industries by boosting productivity and accelerating the process of identifying compounds, speeding up development and approval, improving clinical toral selection and the way drugs are marketed.

Figure 1: Generative AI generates economic value for the pharma and medical product industry, expected value annually ($ billion)